Peptide Marketing Claims: What “For Human Use,” “Compounded,” and “Serum” Actually Mean

Shopping for peptides online can become confusing quickly. One seller describes a freeze-dried peptide. Another promotes a peptide serum. Another says a product is “for human use,” “compounded in the United States,” or “not research use only.” These phrases may sound as if they identify entirely different levels of medical legitimacy.

Some terms do describe real differences in formulation, manufacturing, or the pathway through which a product is supplied. Others mainly describe presentation or marketing. None should be treated as a shortcut around the harder questions: What is the active ingredient? What regulatory pathway applies? What evidence supports the claimed use? What quality testing was performed?

Claim 1: “For human use”

The phrase “for human use” can describe intended use, but it does not by itself show that FDA approved a specific product. FDA explains that compounded drugs are not FDA-approved. The agency does not verify the safety, effectiveness, or quality of each compounded drug before marketing in the same way it reviews an approved drug.

A lawfully compounded medication may still be prescribed and administered to a patient when an approved product cannot meet a clinical need. Those facts can coexist. The medication can be intended for a person and still lack FDA approval.

A better question is: What specific regulatory pathway allows this product to be supplied for human use? Ask whether it is an FDA-approved commercial drug, a patient-specific compounded prescription, a product from a registered outsourcing facility, or something else. The phrase alone does not answer that question.

Claim 2: “Not research use only”

Removing a research-use statement does not create FDA approval. Likewise, placing a research-use statement on a product does not turn every marketing claim into an established scientific fact. The label needs to be evaluated together with the seller’s actual claims, the product category, and the way the product is supplied.

FDA-approved peptide medicines have gone through an established review pathway for specific formulations, manufacturers, doses, uses, and labeling. Other peptides may have limited human data, early experimental evidence, animal studies, or no persuasive clinical evidence for the use being advertised.

FDA has published a list of bulk substances that may present significant safety risks when used in compounding. That page discusses substances such as BPC-157, CJC-1295, MOTs-C, Semax, Selank, and Epitalon, often noting limited safety information, peptide-related impurity concerns, or potential immunogenicity. The presence of research does not mean a product has been approved for patient use.

Claim 3: “From a U.S.-licensed compounding pharmacy”

This claim can communicate useful information, but it still requires context. Compounding occurs within regulated pharmacy and medical frameworks. FDA describes section 503A conditions for certain state-licensed pharmacies and physicians, and section 503B conditions for registered outsourcing facilities. The requirements and oversight are not identical.

A licensed pharmacy is different from an unidentified seller filling vials without a clear pharmaceutical framework. Even so, the finished compounded drug is not automatically FDA-approved. FDA also limits which bulk drug substances may be used under the compounding provisions.

Ask for the name of the pharmacy, whether a prescription is required, which pathway applies, and what product is actually being dispensed. A pharmacy license identifies the supplier and oversight setting. It does not transfer FDA approval to every compounded preparation.

Claim 4: “It is a serum, not a freeze-dried peptide”

“Serum” is a flexible marketing and formulation term. Depending on context, it may refer to a liquid, a topical cosmetic-style product, or another prepared solution. The word does not establish a higher regulatory or clinical status.

Freeze-drying, also called lyophilization, removes water from a product. A lyophilized product may later be reconstituted. A product can also be supplied in liquid form. These differences can affect storage, stability, concentration, packaging, and handling. FDA guidance for lyophilized products discusses separate stability considerations before and after reconstitution.

Formulation and regulatory status remain separate questions. Turning a peptide into a liquid does not make the active ingredient approved. Calling a liquid a serum does not establish sterility, stability, effectiveness, or suitability for injection.

Claim 5: “99% purity”

Purity matters, but it is only part of the quality picture. A reported chromatographic purity value may provide useful information about the sample and method tested. It does not automatically establish:

• the amount of active ingredient in the vial
• the identity of the material
• sterility or bacterial endotoxin limits
• freedom from visible or subvisible particles
• stability throughout storage and shipping
• the independence or competence of the laboratory
• that the certificate matches the batch being sold
• that the substance is safe or effective in humans

FDA urges compounders to know their bulk substance suppliers, understand the testing performed, and obtain valid certificates of analysis. FDA manufacturing guidance also treats identity, purity, supplier qualification, specifications, and testing as related but distinct controls. Learn more in How Do You Read a Certificate of Analysis? and Quality Control Basics.

Claim 6: “Clinically proven”

Ask what was actually studied. Was the specific molecule tested in humans? Was the same formulation, route, dose, duration, and intended use studied? How many people participated? Was there a comparison group? Were clinically meaningful outcomes reported?

A publication about a molecule does not validate every product or every marketing claim built around it. FDA has specifically addressed promotion of non-FDA-approved compounded GLP-1 drugs, including unsupported statements that compounded products are the same as approved drugs or are clinically proven to produce patient results.

“Research exists” and “clinically proven for this product and use” are different statements. Reliable marketing should make that distinction clear.

Separate four questions before deciding what a claim means

1. What is the active substance?

Start with the molecule. Identify whether the product contains semaglutide, tirzepatide, BPC-157, TB-500, CJC-1295, GHK-Cu, or another substance. Similar-sounding names and blends can hide important differences.

2. What is the formulation?

Determine whether it is freeze-dried, already in solution, topical, combined with another ingredient, or packaged for another route. These facts describe the form of the product. They do not decide approval status.

3. How is it supplied?

Distinguish among an FDA-approved prescription drug, a compounded prescription, a registered outsourcing-facility product, a cosmetic, a dietary supplement, and a laboratory research product. These categories carry different rules and expectations.

4. What evidence supports the advertised use?

Look for evidence that matches the molecule, route, formulation, population, and claimed outcome. A polished website, a white coat, or a pharmacy-style label cannot substitute for evidence.

The PepMarket rule: translate reassuring phrases into questions

• “For human use”: Under which regulatory pathway?
• “Compounded in the USA”: By which pharmacy or facility, and under what conditions?
• “Peptide serum”: What is the active ingredient, route, and formulation?
• “99% pure”: What was tested, by whom, with which method, and what additional quality testing was performed?
• “Clinically proven”: Which human study supports this exact product and claim?
• “Not research use only”: What independently establishes the product’s regulatory status?

For more background on category language, see Lab Grade vs. Research Grade. For formulation context, see Lyophilized Compound Handling.

One phrase with a specific regulatory meaning

“FDA-approved” refers to a specific product reviewed through an established approval pathway. Approval is tied to defined manufacturing, formulation, labeling, and intended-use details. A compounded version does not inherit approval simply because an approved product contains a similar active ingredient. An experimental peptide does not become approved because a licensed professional prescribes or compounds it.

When a marketing claim becomes a safety concern

Pause when a seller promises guaranteed outcomes, minimizes the difference between compounded and approved products, will not identify the pharmacy or manufacturer, treats a purity percentage as complete quality assurance, or encourages unsupervised human use of a research product.

If you are considering a medication, discuss the exact product with a licensed prescriber and pharmacist. If you have already used a product and develop severe, persistent, or worsening symptoms, seek prompt medical care. For a suspected emergency, call emergency services. Do not use a marketing label to decide whether a serious reaction needs attention.

The bottom line

Peptide marketing is filled with words that can sound more conclusive than they are. “For human use” is not the same as FDA-approved. “Compounded” is not the same as FDA-approved. “Serum” is not proof of greater safety or legitimacy. “99% purity” is not comprehensive pharmaceutical quality testing. “Research exists” is not the same as “clinically proven.”

The safest approach is to separate the molecule, formulation, supply pathway, quality evidence, and clinical evidence. That turns reassuring language into questions that can be checked.